Al Bentley
4 min read
McKesson has been a powerful wealth creator over the past several years, which naturally raises a sharper question for anyone looking at the stock today. Are the cash flows this healthcare distributor can generate enough to support a share price that now sits above US$1,000?
-
Over 5 years the stock has returned about 382%, which makes the link between McKesson’s current valuation and its underlying cash generation especially important for anyone considering fresh capital.
-
Recent earnings commentary highlighted momentum in pharmaceutical distribution and specialty services, along with acquisitions such as Precision Medicine Group, which can affect expectations for how much cash the business might produce and when those inflows arrive.
-
Prefer to judge McKesson on earnings? See what McKesson’s 26.1x P/E says about the price.
The issue now is whether the cash flows implied by McKesson’s current operations and investments are sufficient to justify where the share price trades today.
If you are weighing McKesson at over US$1,000 a share and want a broader reference point on valuation grounded in cash flow and balance sheet strength, a focused screener built around 36 high quality undervalued stocks can be a useful next step for research.
Is McKesson a Bargain on Cash Flow?
The Discounted Cash Flow model looks at the cash McKesson can return to shareholders over time and then adjusts those amounts back to today’s dollars. On this view, the business is generating sizeable liquidity already, with latest twelve month free cash flow of about $6.7b and analyst projections that keep future cash generation in the multi billion range rather than relying on a sharp step change.
Across the next decade, the DCF uses a two stage pattern where free cash flow is expected to grow from current levels and then settle into slower expansion, which fits a mature distributor more than an early stage growth story. Despite management raising full year adjusted EPS guidance to $46 at the midpoint in the latest Q3 CY2026 update, the DCF estimates indicate that McKesson’s intrinsic worth is substantially above the current share price of $1,062.16, so the market price does not fully reflect those projected cash flows today. Find out what McKesson could be worth using our Discounted Cash Flow (DCF) estimate.
The McKesson Narrative: What Would Justify Today’s Price?
Narratives pick up where the McKesson valuation puzzle leaves off, explaining which assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or materially less than today’s price on Simply Wall St’s Community page. Each Narrative treats McKesson’s fair value as a specific thesis about the business that can be tracked over time, rather than a static one off snapshot.